Abstract This study examines inhibiting galectin 1 (Gal1) as a treatment option for hepatocellular carcinoma (HCC). Gal1 has immunosuppressive and cancer-promoting roles. Our data showed that Gal1 was highly expressed in
Abstract Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer worldwide. Despite approvals of several therapeutics to treat
Virus infection is known to increase the risk of various cancers, including hepatocellular carcinoma (HCC). In a recent article in Cell, Liu et al. report a blood-based viral exposure
RNA sequencing may help doctors diagnose hepatocellular carcinoma earlier, according to preliminary data presented Sunday (March 31) at the American Association for Cancer Research annual
Created by ePubSystems. Contact Us for similar site for your university or institute.